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ABSTRACT
Structural variation is an important cause of genetic
variation. Whole genome analysis techniques can
efficiently identify copy-number variable regions but
there is a need for targeted methods, to verify and
accurately size variable regions, and to diagnose
large sample cohorts. We have developed a techni-
que based on multiplex amplification of size-coded
selectively circularized genomic fragments, which is
robust, cheaper and more rapid than current multi-
plex targeted copy-number assays.
INTRODUCTION
Genetic variation occurs on multiple levels, from single
nucleotide polymorphisms (SNPs) to larger events invol-
ving contiguous blocks of DNA sequence that vary in
copy number between individuals. The structural diversity
in the human genome is much higher than previously
assumed, and attracts an increased interest within the
genetics community. It is now becoming increasingly clear
that submicroscopic variations are major contributors to
genetic diversity and human disease (1,2).
The interest in copy-number variation (CNV) has led to
the establishment of a number of analytical methods, using
either global or targeted approaches. Microarray-based
comparative genome hybridization (array-CGH) is a
commonly used global approach to CNV detection (3,4),
enabling genome-wide scans for detection of novel CNVs.
CGH arrays are manufactured with diﬀerent resolution
and coverage, using diﬀerent approaches to probe genomic
samples, ranging from BAC clones to short oligonucleo-
tides attached to the array surface (5). High-throughput
SNP analysis can also be employed for CNV-detection, as
revealed by long stretches of apparently homozygous loci
or unusual heterozygous signal ratios (6,7). Although
global array-based approaches can provide high resolution
data on CNVs in individuals, there remains a need for
simple, cost-eﬃcient, accurate methods to validate and test
candidate CNVs across larger populations.
One established targeted approach for CNV analysis is
quantitative PCR (qPCR) (8). However, this technique
requires setting up a large number of replicate reactions
to score individual deletions and duplications, and is
generally not suitable for multiplexing. Similarly, ﬂuores-
cence in situ hybridization (FISH) is a labor-intensive
technique which is not usually highly multiplexed, though
it is well-established in diagnostics laboratories. Examples
of multiplexed targeted copy-number analysis approaches
are Quantitative multiplex PCR of short ﬂuorescent frag-
ments (QMPSF) (9), multiplex ampliﬁable probe hybridi-
zation (MAPH) (10) and multiplex ligation-dependent
probe ampliﬁcation (MLPA) methods (11–13). In MLPA,
which has become perhaps the most commonly used one,
up to 40 loci can be analyzed in parallel.
Here, we present an approach based on the selector
technique (14), called multiplex ligation dependent
genome ampliﬁcation (MLGA). In contrast to MLPA,
genomic DNA is ampliﬁed rather than probe molecules,
and a single probe is required for each target instead
of two. This leads to increasing reaction kinetics and
decreasing probe ampliﬁcation background. Furthermore,
these shorter probes are easily manufactured by conven-
tional oligonucleotide synthesis. These properties allow
for cost-eﬃcient design of custom MLGA assays with a
short turnover time. This is demonstrated in an accom-
panying paper, where a candidate duplication was veriﬁed,
sized, and diagnosed in a very cost-eﬃcient approach
(Salmon Hillbertz,N.H.C. et al., Nat. Genet. in press).
MATERIALS AND METHODS
Selectorprobe design
A set of 14 human target genes were chosen on ﬁve
diﬀerent chromosomes (Table 1). Sequences for each
target were collected from the Ensembl database (www.
ensembl.org, assembly NCBI 36, Oct 2005). These
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to generate a set of restriction fragments using a
restriction enzyme of choice. A single fragment for each
target sequence was then chosen in such a way that the
fragments in each pool were between 100 and 400nt in
length with each fragment having a diﬀerent length, with a
minimum size diﬀerence of 6nt.
Selector probes serving as templates for the circulari-
zation of each chosen target fragment (Table 1) were
designed using the ProbeMaker software (16). Each
selector consists of two synthetic oligonucleotides; a
target-speciﬁc selector probe (70–74nt), and a universal
vector oligonucleotide (34nt). Oligonucleotides were
synthesized by DNA Technology A/S, Denmark
(Table 2). The central part of each selector probe
is complementary to the vector oligonucleotide so that
hybridization between the two generates the recognition
sequence for the Hind III restriction enzyme and a
universal primer pair site for parallel PCR ampliﬁcation.
The ends of the selector probes (18–20nt each) have
sequences complementary to the ends of the restriction
fragments targeted for selection.
DNA samples
Six genomic DNA samples were extracted from blood
(Flexigene, Qiagen), collected with the appropriate per-
missions from individuals diagnosed with Down syn-
drome, and admitted to the Department of Clinical
Genetics, Uppsala University. DNA samples were also
extracted from the aneuploid cell cultures NA04626,
NA01416 and NA06061 (Coriell Cell Repositories) with
3, 4 and 5 X-chromosomes. Pooled samples of male and
female DNA from Promega (cat# G147A 20745001, cat#
G152 20215001) were used as references.
MLGA
Restriction digestion was performed for 30min at 378C
using 8 U of restriction enzyme Mnl I (Fermentas) and
200ng genomic DNA in 5ml of NEB4 buﬀer (New
England Biolabs) supplemented with 0.1mg/ml BSA. The
restriction enzyme was inactivated during 5min at 958C.
Much less DNA can be used, however, and as little as
12.5ng genomic DNA has been used in successful assays
(Salmon Hillbertz,N.H.C. et al., Nat. Genet. in press).
Circularization of restriction fragments was performed
by adding 10ml of a solution containing 33nM vector
oligonucleotide, 0.15nM of each selector, 14.5mM
MgCl2, 1.2mM NAD, 0.3U/ml Ampligase (Epicentre)
and 0.75 PCR buﬀer (Invitrogen) to the restriction
digested DNA. The reactions were incubated with the
following temperature proﬁle: 958C for 5min, followed by
three cycles of 758C 5min, 658C 5min, 608C 5min, 558C
5min and 508C 10min. To enrich for circularized DNA,
15ml of a solution containing 7.5U exonuclease I (New
England Biolabs), 0.13M Tris–HCl (pH 9.0), 3.4mM
MgCl2 and 0.02mg/ml BSA was added. The reaction was
incubated at 378C for 30min, followed by 708C for
10min to inactivate the enzyme.
Table 2. List of oligonucleotides (selectors, vector and primers) used in the MLGA protocol
Oligonucleotide Sequence (50 to 30)
AR GAAATCCTACCCTCCTCTTTACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGTCTTGTAAGTCAAACATTAA
SRY_2 AGCCGAAAAATGGCCATTACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGGCGATCAGAGGCGCAAGA
MADH4 TTAAACAGGCTGAATACTGGACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGTGCTATTAATTGTAAGCTGT
SIM2 GCTGGAACATCCTCCTAAAAACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGCTCCAGAGGCGGTGGCTC
L1CAM AACCAACTCCTCTTCTGCACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGGGGACATGAGGCCATGAC
SOD1 TAGAGCGCTGAAGCCGGAACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGTAGAACAGAGGCCAGCAA
TYMS TCTAAGCAGAAAGGTGGGTACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGCCGCACTCGCTTGTGGTA
ABCC4 GGGTTTTCCCCTCATTCTTACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGTGCTGTTGAGGTACATACAG
SERPINB2 TTGGCACAGGGAAGGAAGACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGCAGGTATACCTGTTGTGAAT
BRCA2 ACATATTCTTCCTCATGTTGACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGACAAAGGGAGGTGATCTAAG
STCH TCATGGTGATGGTGAAGAAAACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGAGTTGAAGAGGTTTGGGC
SRY_1 ACTTACAGCCCTCACTTTCACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGAGGCGAAGATGCTGCCGA
RPS6KA3 TTACTATCAGCCTCACATTTACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGACCCCAGGTTGCTTACAT
NFATC1 CCTGGGGAATTCAGGGGCACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGGGTATTTTCAAAGCCACTTG
Vector CTCGACCGTTAGCAAAGCTTTCTACCGTTATCGT
Fwd. primer AGCTTTGCTAACGGTCGAG
Rev. primer AGCTTTCTACCGTTATCGT
Table 1. List of target loci for the MLGA probe set
Gene/Probe name Chromosome Position in chromosome
Start (nt) Length (nt)
AR X 66684790 102
SRY Y 2715319 112
MADH4 18 46820 996 119
SIM2 21 37017473 132
L1CAM X 152785534 141
SOD1 21 31954636 157
TYMS 18 649034 164
ABCC4 13 94484282 196
SERPINB2 18 59706873 213
BRCA2 13 31792206 236
STCH 21 14669412 252
SRY Y 2714956 290
RPS6KA3 X 20079076 339
NFATC1 18 75257833 358
Chromosome position according to Ensembl assembly NCBI 36,
October 2005.
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adding 6ml of the reaction ( 40ng DNA) to 19ml PCR-
mix, containing 0.9 PCR buﬀer (Invitrogen), 0.66mM
MgCl2, 0.33mM dNTP, 0.13mM each of forward and
reverse primer, 5U Hind III (Fermentas) and 0.5U
Platinum Taq DNA polymerase (Invitrogen). Hind III
was added in the PCR-mixture to create a linear template
for the PCR ampliﬁcation, decreasing the risk of amp-
lifying multiple laps of the circular DNA template.
Temperature cycling was performed as follows: 378C
for 30min, 958C for 5min followed by 30 cycles of 958C
15s, 558C 30s and 728C for 60s followed by 728C for
10min.
PCR products were analyzed using an Agilent
Bioanalyzer 2100
TM instrument and quantiﬁed using the
Agilent 2100 expert software, version B.02.02.SI238.
RESULTS
The MLGA technique employs a number of enzymatic
processing steps (Figure 1a). In brief, sample DNA is ﬁrst
restriction digested to generate genomic fragments with
deﬁned ends. DNA is then denatured and mixed with
a pool of selector probes and a thermostable DNA ligase
to allow hybridization and circularization of the corre-
sponding target fragments. The sample is treated with
exonuclease I to enrich for circularized DNA, and ﬁnally,
the circularized fragments are PCR ampliﬁed using a
universal primer pair. The selector probes are designed
such that the ampliﬁed fragments are of diﬀerent size,
allowing for rapid and simple detection and quantiﬁca-
tion using electrophoretic separation. In order to
evaluate the approach on a model system for CNV,
Sample DNA
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and vector
III. Exonuclease
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Figure 1. (a) Multiplex ligation-dependent genome ampliﬁcation (MLGA), reaction scheme. (I) Genomic DNA is digested by restriction enzyme to
generate targets with deﬁned ends. (II) Each MLGA probe consists of two oligonucleotides, one selector oligo of 70–74nt (green) and one general
vector oligo of 34nt (red). MLGA probe together with DNA-ligase forms circular DNA of target molecules after denaturation and hybridization.
(III) To reduce background signal in the assay, undesirable, linear DNA is degraded by exonuclease I (Exo I). (IV) Multiplex PCR is facilitated by
using universal primers that hybridize to a sequence in the vector. PCR products are analyzed using the Agilent Bioanalyzer 2100
TM electrophoresis
system. (b) Data from an MLGA set of 14 probes targeting loci on human chromosomes 13, 18, 21, X and Y. The upper graph shows the resulting
elution diagrams from analyses of male and female DNA pools.
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chromosomes X, Y, 13, 18 and 21, were designed to
analyze male and female genomic DNA (Figure 1b). To
obtain relative quantiﬁcation, each peak area was normal-
ized by dividing with the sum of areas of all peaks
originating from autosomal targets. The ratios of each
individual probe area were then compared between the
male and female DNA samples. The results show only
marginal diﬀerences in autosomal peak ratios between
the male and female samples, and the expected lack of
Y-chromosome and duplication of X-chromosome signals
in the female sample compared with the male sample
(Figure 1b).
DNA samples prepared from six diﬀerent Down
syndrome patients were analyzed using the same probe
set to conﬁrm that duplications of autosomal chromo-
somes can be detected. All chromosome 21 probes show
a ratio around 1.5 indicating a trisomy, as expected
(Figure 2a). In order to test the linearity and sensitivity
of copy-number measurements, a series of cell lines
carrying 1, 2, 3, 4 and 5 copies of the X-chromosome
were analyzed. Normalization was performed by dividing
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Figure 2. (a) DNA samples prepared from six diﬀerent Down syndrome patients, three males and three females, were analyzed with a set of 14
selector probes distributed over chromosomes 13, 18, 21, X and Y. Data was normalized by dividing each peak area with the sum of the peak areas
of all non chromosome 21 probes. On the x-axis, probes are ordered according to chromosomal position. Ratios between patient and reference
DNA sample values are shown on the y-axis, using sex-matched reference samples. (b) Graph shows the response of X targeting probes to an
increasing number of chromosomes. On the x-axis samples with 1–5 copy of chromosome X are shown, where samples for 1X is male, 2X is female
and 3–5X are aneuploid cell cultures from Coriell Cell Repositories. To illustrate the results, each normalized value was divided by the 2X diploid
sample value.
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(Figure 2b). The increase in signal is linear with a slope of
0.5 units per additional X-chromosome, implying that
the MLGA method is accurate and sensitive enough to
quantify a broad range of copy-number changes.
DISCUSSION
The MLGA is a multiplex targeted approach for copy-
number analysis, which seems well-suited for CNV
measurement and validation. MLGA has several advan-
tages over the commonly used multiplexed targeted copy-
number assay MLPA. First, MLGA probes are easier and
cheaper to manufacture, as only one probe is required
per locus and they are similar in size and relatively short
(70–74nt). Extensive puriﬁcation is not required since the
probes do not need functional ends in contrast to MLPA
probes, and also no modiﬁcation of the 50 end. Second,
a uni-molecular circularization reaction is inherently
more rapid and eﬃcient than a bi-molecular ligation
reaction (17). Moreover, probe ampliﬁcation methods,
such as MLPA, suﬀer from probe-dependent and target-
independent ampliﬁcation artifacts (17). Therefore, very
low concentrations of probes are used in the MLPA,
resulting in a requirement for long hybridization times to
saturate the target sequences.
For assays that could be applied in the diagnostic
setting, time is a critical factor. With MLGA, the total
assay time, including electrophoresis, is 5h, relative to the
 24h assay time for the MLPA. Another important
aspect for custom loci is the turn-over time in assay
design, particularly when sizing duplications/deletions,
which typically requires an iterative process to map
the chromosomal break points. An MLGA assay can be
set up in  5 days, including oligonucleotide design and
synthesis, and two rounds of experimental optimization
and veriﬁcation of the assay. Finally, the MLGA assay
can potentially create longer PCR products than MLPA,
since the length of the product is deﬁned by the genomic
DNA sequence rather than by the length of synthetic
probes. This ﬂexibility in PCR product length may allow
for higher levels of multiplexing.
In a separate study, we applied the technique for veriﬁ-
cation and sizing of a CNV (Salmon Hillbertz,N.H.C.
et al., Nat. Genet. in press). We investigated a suspected
duplication involving an SNP identiﬁed during the course
of genome-wide SNP analyses of diﬀerent dog breeds.
The distance between the closest ﬂanking SNPs was
930kb, so we initially designed MLGA probes with
100kb spacing over 2Mb, including a fragment containing
the SNP. Two probes, including the fragment with the
SNP, responded with a 2-fold increase in homozygous
dogs compared with control fragments, and with 1.5-fold
increase in heterozygous dogs, thus verifying that the
region indeed was duplicated. We then designed a new set
of probes with 10kb spacing, ﬂanking the copy-number
positivefragments,totrytomorepreciselydeﬁnethesizeof
the duplication. Using a ﬁnal set of probes, the duplicated
region could be deﬁned suﬃciently well to design a PCR
primer pair that ampliﬁed across the duplication break
point. The PCR fragment was sequenced and the size of
the duplication was determined to be 133.4kb. Finally,
a diagnostic MLGA assay was compiled to screen 72 dogs.
The phenotype, experimental details and implication of
the duplication are described in Salmon Hillbertz,N.H.C.
et al., (Nat. Genet. in press)
One potential disadvantage compared to the MLPA
approach, is that a larger proportion of the sequence
in the ﬁnal PCR product is deﬁned by genomic DNA
sequences. This can potentially introduce a bias in
ampliﬁcation rates due to the diversity in sequence. This
though can be addressed by applying stringent criteria
during the in silico design process of each probe set. From
a number of applied MLGA projects, we have learnt that
75–80% of designed selector probes reproducibly select
a fragment of the intended size. There may be several
reasons for this non-complete assay conversion rate. We
have previously shown that high GC content (>60%) in
the selected fragment decreases the probability of a probe
being successful (14). The GC content can aﬀect both
the circularization and PCR ampliﬁcation yield, possibly
due to secondary structures interfering with probe and
primer hybridization and/or extension. Such secondary
structures may also be present in DNA fragments with
a lower GC-content, escaping our GC-content design
threshold.
We expect to be able to develop better design criteria to
improve success as more assays are developed and can be
evaluated. Since selected fragments are in the order of
100bp and CNVs are often in the order of several
kilobases, positional constraints on design are quite low.
There are, on average, four selectable restriction fragments
to choose among per kilobase of genomic DNA sequence,
since we are using restriction enzymes with 4bp recogni-
tion sequences. It is possible to further increase freedom of
design by introducing a site-speciﬁc cleavage of the target
strand, making the design only depending on a restriction
recognition site at the 30 end of the target fragment
(14). The ﬁrst-trial success rate among diﬀerent DNA
samples is about 90–95% (data not shown). Data
from failing subjects can be rescued by collecting new
DNA samples.
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